FcRn inhibition targets the persistence of pathogenic IgG rather than its production. The panel explains why this downstream ...
One-year data from the phase 3 AQUARELLE study show that divozilimab (Biocad), an anti-CD20 monoclonal antibody, reduced ...
AV-1959R is an investigational amyloid-beta vaccine from Nuravax. The FDA granted it Fast Track designation for preventing Alzheimer disease in cognitively unimpaired people with biomarker evidence of ...
Open-label extension data showed that disability trends observed with vidofludimus calcium during the double-blind period of the phase 2 CALLIPER trial persisted with continued treatment in ...
This episode, titled ‘Differentiating FcRn-Targeted Therapies in MG Clinical Practice,’ features panelists examining ...
Clene has filed an NDA seeking accelerated approval of CNM-Au8 for ALS, following 2 missed primary trial endpoints and years of evolving FDA guidance. Catch up on any of the neurology headlines you ...
Clene has filed an NDA seeking accelerated approval of CNM-Au8 for ALS, following 2 missed primary trial endpoints and years ...
Decade of OPERA Data Supports Early Ocrelizumab Treatment Initiation in Relapsing Multiple Sclerosis
A newly published study showed that patients with relapsing multiple sclerosis (RMS) who started ocrelizumab (Ocrevus; ...
A four-year-old with regression, ptosis, and feeding problems illustrates the textbook features of severe early-onset TK2D ...
This week on NeurologyLive, there are a number of hot topics that we will be post ...
Intravenousocrelizumab (Ocrevus; Genentech) demonstrated noninferiority to oral fingolimod (Gilenya; Novartis) for ...
Welcome to NeurologyLive® 's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive 's widespread coverage in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results